Peptides for Neuropathy
The peptides people most often research for neuropathy, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 4
- With human trials
- 0
- FDA approved (any use)
- 0
- SemaxACTH(4-10) analogNo study with an outcome for neuropathyPubMed search, 11 Oct 2026Human2Animal0Summarised0PCAC voted 8–5 for 503A (Jul 2026)Overview
- BPC-157Gastric pentadecapeptideAnimal evidence, 2 of 4Regulatory peptides 2010, PMID 19903499Human0Animal2Summarised1PCAC voted 8–6 for 503A (Jul 2026)Overview
- TB-500Synthetic fragment of thymosin beta-4No study with an outcome for neuropathyPubMed search, 11 Oct 2026Human1Animal6Summarised0PCAC voted 8–6 for 503A (Jul 2026)Overview
- SelankTuftsin analogNo study with an outcome for neuropathyPubMed search, 11 Oct 2026Human0Animal0Summarised0Not FDA approved · research chemicalOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What nerve damage means here
MedlinePlus says peripheral nerve disorders happen when one or more peripheral nerves are damaged.[18]
Depending on which nerves are involved, it says people may have pain, trouble walking or a variety of other problems.[18]
What the listed peptides were tested on
PubMed records matching the site's neuropathy search: Semax 2 human-only and 0 animal-only; BPC-157 0 human-only and 2 animal-only; TB-500 1 human-only and 6 animal-only; Selank 0 human-only and 0 animal-only.
Calculated from goal neuropathy; ledger date 2026-10-02; counts semax (human only 2, animal 0, rct 0), bpc-157 (human only 0, animal 2, rct 0), tb-500 (human only 1, animal 6, rct 0), selank (human only 0, animal 0, rct 0). Formula: Copied from web/src/data/goals.json: peptides[].ledger.humanOnly.n and ledger.animal.n for this goal (PubMed title/abstract search, humans[mh] NOT animals vs animals NOT humans).
BPC-157's nerve result here is a rat sciatic nerve transection model, a traumatic injury rather than diabetic or chemotherapy neuropathy; BPC-157 markedly improved nerve healing in rats.[1]
Semax's reports on nerve disease here are in the optic nerve, not peripheral nerves: in patients with optic nerve disease, adding semax had a favorable impact on the intensity and rate of recovery and improved visual functions.[19]
In glaucomatous optic neuropathy, a neuroprotective complex that included semax showed advantages over traditional neuroprotective treatment on electrophysiological and computer examination.[20]
For TB-500 the nearest result is full-length thymosin beta-4 after stroke in rats, which improved neurological outcome at 2 and 12 mg/kg from day 14.[21]
Common questions
What is the best peptide for neuropathy?
No peptide here has a diabetic or chemotherapy neuropathy trial in the cited evidence; the support is a rat nerve-transection study for BPC-157 and optic nerve reports for Semax.[1]
Can BPC-157 repair nerve damage?
In rats with a transected sciatic nerve it markedly improved nerve healing; no human nerve trial is in the evidence files.[1]
Explore nearby goals
Sources
- 1Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.Regulatory peptides · 2010PMID 19903499Accessed 2 Oct 2026
- 2PubMed search: semax[tiab] (208 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: semax[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (selank[tiab] OR semax[tiab]) AND (randomized[tiab] OR patients[tiab] OR clinical[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: selank[tiab] (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: selank[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: semax[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 15PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 16PubMed search: ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17PubMed search: selank[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 18Official web pageOfficial web page · web page
- 19[Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease].Vestnik oftalmologii · 2000PMID 10741256Accessed 2 Oct 2026
- 20[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].Vestnik oftalmologii · 2001PMID 11569188Accessed 2 Oct 2026
- 21A dose-response study of thymosin β4 for the treatment of acute stroke.Journal of the neurological sciences · 2014PMID 25060418Accessed 2 Oct 2026
Found an error? Report a correction.